Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of black cumin seed oil (derived from *Nigella sativa*) and omega-3 fatty acids (typically EPA and DHA) investigated for its immunomodulatory and anti-inflammatory properties. Black cumin seed oil contains the bioactive compound thymoquinone, which exhibits antioxidant effects and inhibits pro-inflammatory pathways such as NF-κB and COX-2. Omega-3 fatty acids further contribute to the reduction of systemic inflammation by serving as substrates for anti-inflammatory lipid mediators. This combination is primarily explored as a supportive therapy to enhance immune function and mitigate the inflammatory response associated with viral infections like COVID-19, as well as in metabolic and cardiovascular conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on black cumin seed oil + omega-3 fatty acids.